Swiss Life Asset Management’s ImmunityBio IBRX Stock Holding History

Swiss Life Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Buy	26,177 +2,741	+12%	+$20.7K	﹤0.01%	1444
2026 Q1	$180K	Buy	23,436 +7,020	+43%	+$48.1K	﹤0.01%	1410
2025 Q4	$32.5K	Buy	16,416 +5,459	+50%	+$12.4K	﹤0.01%	1372
2025 Q3	$27K	Buy	+10,957	New	+$28.2K	﹤0.01%	1186

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Swiss Life Asset Management's IBRX Position: Q2 2026 in Review

Swiss Life Asset Management increased its ImmunityBio (IBRX) stake by 12% in Q2 2026, buying an estimated $20.7K and bringing the position to 26,177 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Swiss Life Asset Management first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. 273 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Swiss Life Asset Management held 26,177 shares of ImmunityBio worth $229K as of Q2 2026.
Swiss Life Asset Management bought 2,741 ImmunityBio shares in Q2 2026, an estimated $20.7K.
ImmunityBio made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1444 holding.
Swiss Life Asset Management first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
273 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.